Normal Museum holds 2nd annual International Day of Women and Girls Science
NORMAL, Ill. (WMBD) — The Children's Discovery Museum in uptown Normal held its 2nd annual International Day of Women and Girls in Science.
At the event were 10 local STEAM organizations that gave kids a hands-on experience with science, technology, engineering, art and math.
Kids practiced being doctors, experimented with water power and checked out geology experiments to name a few of the many activities.
They also heard from women with STEAM-related careers like nurses, engineers and biologists.
Nick Papineau with the museum said it's a great way to expose kids to STEAM at a young age.
'We want them to see themselves as problem solvers, and that extends beyond a job, it extends into social life. It extends into just basic things at home, so it is becoming more of a community member,' said Papineau.
He said one-third of people in the steam workforce are women.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Hundreds of Bronx students shine at STEM expo at Yankee Stadium
THE BRONX, N.Y. (PIX11) — It's the third annual STEM Expo at Yankee Stadium! More than 400 students took part in the borough-wide STEM and science fair. From as young as 4 to eighteen years old, Bronx students had a blast inside Yankee Stadium, showcasing their love for science. More Local News Students presented the culmination of their hard work throughout the school year to one another, with hundreds of Bronx's best students presenting their final projects, covering science, math, engineering, gaming, and even robotics. Presentations included a robot that could plant wildflowers, experiments attempting solutions to rising sea levels, and projects delving into finding cures for cancer. Brian Smith with the Yankees says the yearly event is all about empowering the next generation of leaders. The competition is fierce, and everybody gets a medal and an experience of a lifetime. At times, it felt like the students were the teachers for the day. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
11 hours ago
- Yahoo
Kīlauea shows signs of new eruption
Kīlauea is stirring again. Scientists at the Hawaiian Volcano Observatory say signs of a new eruption episode began early Tuesday morning inside Halemaʻumaʻu crater. Kilauea eruption paused, but likely to begin again Around 5:54 a.m. HST, lava overflowed from the volcano's north vent cone and started spreading across the crater floor. What began as scattered spattering overnight became more continuous in the early morning hours, officials said. The next full eruption episode is expected to begin sometime between Wednesday and Thursday, though scientists caution that high lava fountains could erupt as early as types of eruptions have become somewhat predictable in recent months. Since December 2024, Halemaʻumaʻu has seen a series of lava fountaining episodes, typically lasting less than a day and followed by multi-day pauses. So far, all volcanic activity remains confined within Hawaii Volcanoes National Park. The volcano's alert level remains at Watch, and the aviation color code is Orange. Officials say they'll issue another alert once sustained lava fountains signal the official start of Episode 25. Download the free KHON2 app for iOS or Android to stay informed on the latest news Live video streams and updates can be found on the U.S. Geological Survey's website and YouTube channel. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
17 hours ago
- Yahoo
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and solid tumors, today announced that clinical data for its next-generation COVID-19 multi-antigen vaccine candidate, GEO-CM04S1, will be presented at the European Hematology Association (EHA) 2025 Hybrid Congress, taking place June 1215, 2025, in Milan, Italy and online. Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center in Duarte, California, will present a poster titled: "MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study". The poster will be featured on Saturday, June 14, 2025, from 18:30 to 18:30 CEST in the Poster Hall, as part of the session on Infections in Hematology (including supportive care/therapy). The presentation will highlight initial results from a Phase II randomized clinical trial highlighting the superior cellular immune response of GEO-CM04S1 compared to an authorized mRNA-based COVID-19 vaccine in CLL patients - a population known to exhibit suboptimal protective responses to COVID-19 and other vaccines due to immune dysfunction. The findings will underscore the differentiated mechanism and clinical potential of the GeoVax MVA multi-antigen platform, particularly in immunocompromised individuals. "GEO-CM04S1 continues to show promise as a vaccine option for populations with suboptimal protection from existing COVID-19 vaccines," said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. "We are proud to have these important data showcased at EHA2025, reflecting the real-world needs of patients with hematologic malignancies." About GEO-CM04S1 GEO-CM04S1 is a multi-antigen COVID-19 vaccine designed using a synthetic Modified Vaccinia Ankara (MVA) vector platform. The vaccine expresses both spike (S) and nucleocapsid (N) antigens of SARS-CoV-2, aiming to provide broader and more durable immune protection. It is currently being evaluated in Phase 2 clinical trials in both immunocompromised and healthy adults. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Company Contact:info@ Investor Relations Contact:geovax@ Sign in to access your portfolio
